サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1424963

移植診断の世界市場：市場規模・シェア分析、技術別、提供内容別、移植の種類別、用途別、エンドユーザー別- 産業需要予測 (～2030年)

Transplant Diagnostics Market Size and Share Analysis by Technology, Offering, Transplant Type, Application, End User - Global Industry Demand Forecast to 2030
出版日: | 発行: Prescient & Strategic Intelligence | ページ情報: 英文 340 Pages | 納期: 2～3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
移植診断の世界市場：市場規模・シェア分析、技術別、提供内容別、移植の種類別、用途別、エンドユーザー別- 産業需要予測 (～2030年)
出版日: 2023年12月01日
発行: Prescient & Strategic Intelligence
ページ情報: 英文 340 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 目次
概要

世界の移植診断市場は、2023年には46億8,670万米ドルで、2029年末までに7.5%の成長率で成長し、2030年には77億1,350万米ドルに達します。

これは、臓器置換術の必要性が高まっていること、臓器置換術前の診断処置の必要性が高まっていること、感染症が増加していることに起因しています。

また、最終段階の臓器不全の患者数は増加傾向にあり、臓器移植手術の発展により、多くの患者がこれらの手術を受けられるようになっています。

技術別では、分子アッセイが2023年に65%のシェアで業界をリードしており、今後も優位を保つと思われます。

これは、分子アッセイがレシピエントとドナーの適合性を検査するための手術前診断プロセスで広く使用されているという事実によるものです。これらのアッセイは、非分子アッセイとは対照的に、多数のサンプルの研究、瞬時の分析、高い手続き上の有効性など、技術的な利点があるため、主に受け入れられています。

ソフトウェア・サービス部門は今後最も急速に成長すると思われます。これは、市場競合において各社が提供するソフトウェアの定期的なアップデートと充実したサービスが理由です。

さらに、より先進的な機器の拡大により、技術職員に機器の取り扱いや使い方を教えるための講習会の需要が急増しています。これらの要因が業界の進化につながっています。

移植診断市場は、2023年には診断薬カテゴリーが70%のシェアを占めており、今後もこの傾向が続くと思われます。これは、病気の発生が増加しているためです。

さらに、診断カテゴリーは移植前診断と移植後診断に分けられます。さらに、移植プロセスでは、移植の適合性を確認するために移植前にすべての相対的な診断検査が行われます。例えば、血液プロファイリング、組織適合性検査、伝染病検査などです。

2023年には北米が50%と最大のシェアを占めており、今後もこの傾向は続くと思われます。これは、最先端の技術や分析ツールの高い受容率、高額の医療費、熟練した専門家の入手可能性、軟部組織移植、幹細胞療法、オーダーメイド薬の広範な使用と大いに関係があります。

さらに、臓器移植の件数の増加、移植に対する意識の高まり、伝染病の罹患率の増加、慢性疾患にかかりやすい高齢者人口の増加が、この業界の原動力となっています。

当レポートでは、世界の移植診断の市場について分析し、市場の基本構造・最新情勢や主な促進・抑制要因、世界全体および地域別・主要国の市場規模の動向見通し (金額ベース、2017～2030年)、技術別・提供内容別・移植の種類別・用途別・エンドユーザー別の詳細動向、現在の市場競争の状況、主要企業のプロファイルなどを調査しております。

目次

第1章 調査範囲

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場指標

第5章 業界の展望

  • 市場力学
    • 動向
    • 促進要因
    • 抑制要因/課題
    • 促進要因/抑制要因の影響分析
  • 新型コロナウイルス感染症 (COVID-19) の影響
  • ポーターのファイブフォース分析

第6章 世界市場

  • 概要
  • 市場収益：技術別 (2017～2030年)
    • 分子アッセイの市場収益：種類別 (2017～2030年)
    • 非分子アッセイの市場収益：種類別 (2017～2030年)
  • 市場収益：提供内容別 (2017～2030年)
  • 市場収益：移植の種類別 (2017～2030年)
    • 固形臓器の市場収益：種類別 (2017～2030年)
  • 市場収益：用途別 (2017～2030年)
  • 市場収益：エンドユーザー別 (2017～2030年)
  • 市場収益：地域別 (2017～2030年)

第7章 北米市場

  • 概要
  • 市場収益：技術別 (2017～2030年)
    • 分子アッセイの市場収益：種類別 (2017～2030年)
    • 非分子アッセイの市場収益：種類別 (2017～2030年)
  • 市場収益：提供内容別 (2017～2030年)
  • 市場収益：移植の種類別 (2017～2030年)
    • 固形臓器の市場収益：種類別 (2017～2030年)
  • 市場収益：用途別 (2017～2030年)
  • 市場収益：エンドユーザー別 (2017～2030年)
  • 市場収益：国別 (2017～2030年)

第8章 欧州市場

第9章 アジア太平洋市場

第10章 ラテンアメリカ市場

第11章 中東・アフリカ (MEA) 市場

第12章 米国市場

  • 概要
  • 市場収益：技術別 (2017～2030年)
    • 分子アッセイの市場収益：種類別 (2017～2030年)
    • 非分子アッセイの市場収益：種類別 (2017～2030年)
  • 市場収益：提供内容別 (2017～2030年)
  • 市場収益：移植の種類別 (2017～2030年)
    • 固形臓器の市場収益：種類別 (2017～2030年)
  • 市場収益：用途別 (2017～2030年)
  • 市場収益：エンドユーザー別 (2017～2030年)

第13章 カナダ市場

第14章 ドイツ市場

第15章 フランス市場

第16章 英国市場

第17章 イタリア市場

第18章 スペイン市場

第19章 日本市場

第20章 中国市場

第21章 インド市場

第22章 オーストラリア市場

第23章 韓国市場

第24章 ブラジル市場

第25章 メキシコ市場

第26章 サウジアラビア市場

第27章 南アフリカ市場

第28章 アラブ首長国連邦 (UAE) 市場

第29章 競合情勢

  • 市場参入企業とその提供製品/サービスの一覧
  • 主要企業の競合ベンチマーク
  • 主要企業の製品ベンチマーク
  • 最近の戦略展開状況

第30章 企業プロファイル

  • bioMerieux S.A.
  • Thermo Fisher Scientific Inc.
  • Bio-Rad Laboratories Inc.
  • Abbott Laboratories
  • Hologic Inc.
  • F. Hoffmann-La Roche Ltd.
  • Laboratory Corporation of America Holdings
  • BAG Diagnostics GmbH
  • Illumina Inc.

第31章 付録

目次
Product Code: 11958

The transplant diagnostics market was valued at USD 4,686.7 million in 2023, and it will grow at a rate of 7.5% by the end of this decade, to touch USD 7,713.5 million by 2030.

This is attributable to the growing requirement for organ replacement procedures, the growing requirement for diagnostic procedures before organ replacement, and the powering occurrence of communicable diseases.

Also, the number of people with final-stage organ failure is on the rise, and because of the development in organ transplantation procedures, a high number of patients can now access these surgeries.

On the basis of technology, molecular assay led the industry with a share, of 65%, in 2023, and it will continue to dominate in the future as well.

This is due to the fact that molecular assays are extensively used in presurgical diagnostic processes for testing the compatibility of a recipient and donor. These assays are mostly accepted because of their tech benefits as opposed to non-molecular assays, for example the study of numerous samples and instantaneous analysis and high procedural efficacy.

The software & services category will grow the fastest in the future. This is because of the regular updates in software and enhanced services provided by the market players remain in the competition.

Furthermore, the expansion of more progressive instruments has led to a surge in the demand for training sessions to teach technical employees to handle and use an instrument. These factors led to the evolution of the industry.

The diagnostics category dominated the transplant diagnostics market, with a share of 70%, in 2023, and it will continue like this in the future. This is credited to the increasing occurrence of ailments.

Furthermore, the diagnostic category is divided into pre-transplantation and post-transplantation diagnostic. Additionally, for transplant processes, all relative diagnostic tests will be done prior to the transplant to see the compatibility of the transplant for example blood profiling, histocompatibility testing, and communicable disease testing.

North America had the largest share, of 50%, in 2023, and it will continue like this in the future. This has a lot to do with the high acceptance rate of cutting-edge techniques and analytic tools, high healthcare spending, the obtainability of skilled experts, and the extensive use of soft tissue transplants, stem cell therapies, and tailored medications.

Furthermore, the growing count of organ replacements, the increasing consciousness of transplantation, the growing incidence of communicable ailments, and the rising elderly populace susceptible to chronic ailments are powering the industry.

There is an increasing number of organ transplants happening around the world, and this will power the demand for transplant diagnostic solutions. The trend will continue in the years to come as well.

Top Providers of Transplant Diagnostics Are:

bioMerieux S.A.

Thermo Fisher Scientific Inc.

Bio-Rad Laboratories, Inc.

Abbott Laboratories

Hologic Inc.

F. Hoffmann-La Roche Ltd.

Laboratory Corporation of America Holdings

BAG Diagnostics GmbH

Illumina Inc.

Table of Contents

Chapter 1. Research Scope

  • 1.1. Research Objectives
  • 1.2. Market Definition
  • 1.3. Analysis Period
  • 1.4. Market Size Breakdown by Segments
    • 1.4.1. Market size breakdown, by technology
    • 1.4.2. Market size breakdown, by offering
    • 1.4.3. Market size breakdown, by transplant type
    • 1.4.4. Market size breakdown, by end user
    • 1.4.5. Market size breakdown, by application
    • 1.4.6. Market size breakdown, by region
    • 1.4.7. Market size breakdown, by country
  • 1.5. Market Data Reporting Unit
    • 1.5.1. Value
  • 1.6. Key Stakeholders

Chapter 2. Research Methodology

  • 2.1. Secondary Research
    • 2.1.1. Paid
    • 2.1.2. Unpaid
    • 2.1.3. P&S Intelligence database
  • 2.2. Primary Research
  • 2.3. Market Size Estimation
  • 2.4. Data Triangulation
  • 2.5. Currency Conversion Rates
  • 2.6. Assumptions for the Study
  • 2.7. Notes and Caveats

Chapter 3. Executive Summary

Chapter 4. Market Indicators

Chapter 5. Industry Outlook

  • 5.1. Market Dynamics
    • 5.1.1. Trends
    • 5.1.2. Drivers
    • 5.1.3. Restraints/challenges
    • 5.1.4. Impact analysis of drivers/restraints
  • 5.2. Impact of COVID-19
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Bargaining power of buyers
    • 5.3.2. Bargaining power of suppliers
    • 5.3.3. Threat of new entrants
    • 5.3.4. Intensity of rivalry
    • 5.3.5. Threat of substitutes

Chapter 6. Global Market

  • 6.1. Overview
  • 6.2. Market Revenue, by Technology (2017-2030)
    • 6.2.1. Molecular assay market revenue, by type (2017-2030)
    • 6.2.2. Non-molecular assay market revenue, by type (2017-2030)
  • 6.3. Market Revenue, by Offering (2017-2030)
  • 6.4. Market Revenue, by Transplant Type (2017-2030)
    • 6.4.1. Solid organ market revenue, by type (2017-2030)
  • 6.5. Market Revenue, by Application (2017-2030)
  • 6.6. Market Revenue, by End User (2017-2030)
  • 6.7. Market Revenue, by Region (2017-2030)

Chapter 7. North America Market

  • 7.1. Overview
  • 7.2. Market Revenue, by Technology (2017-2030)
    • 7.2.1. Molecular assay market revenue, by type (2017-2030)
    • 7.2.2. Non-molecular assay market revenue, by type (2017-2030)
  • 7.3. Market Revenue, by Offering (2017-2030)
  • 7.4. Market Revenue, by Transplant Type (2017-2030)
    • 7.4.1. Solid organ market revenue, by type (2017-2030)
  • 7.5. Market Revenue, by Application (2017-2030)
  • 7.6. Market Revenue, by End User (2017-2030)
  • 7.7. Market Revenue, by Country (2017-2030)

Chapter 8. Europe Market

  • 8.1. Overview
  • 8.2. Market Revenue, by Technology (2017-2030)
    • 8.2.1. Molecular assay market revenue, by type (2017-2030)
    • 8.2.2. Non-molecular assay market revenue, by type (2017-2030)
  • 8.3. Market Revenue, by Offering (2017-2030)
  • 8.4. Market Revenue, by Transplant Type (2017-2030)
    • 8.4.1. Solid organ market revenue, by type (2017-2030)
  • 8.5. Market Revenue, by Application (2017-2030)
  • 8.6. Market Revenue, by End User (2017-2030)
  • 8.7. Market Revenue, by Country (2017-2030)

Chapter 9. APAC Market

  • 9.1. Overview
  • 9.2. Market Revenue, by Technology (2017-2030)
    • 9.2.1. Molecular assay market revenue, by type (2017-2030)
    • 9.2.2. Non-molecular assay market revenue, by type (2017-2030)
  • 9.3. Market Revenue, by Offering (2017-2030)
  • 9.4. Market Revenue, by Transplant Type (2017-2030)
    • 9.4.1. Solid organ market revenue, by type (2017-2030)
  • 9.5. Market Revenue, by Application (2017-2030)
  • 9.6. Market Revenue, by End User (2017-2030)
  • 9.7. Market Revenue, by Country (2017-2030)

Chapter 10. LATAM Market

  • 10.1. Overview
  • 10.2. Market Revenue, by Technology (2017-2030)
    • 10.2.1. Molecular assay market revenue, by type (2017-2030)
    • 10.2.2. Non-molecular assay market revenue, by type (2017-2030)
  • 10.3. Market Revenue, by Offering (2017-2030)
  • 10.4. Market Revenue, by Transplant Type (2017-2030)
    • 10.4.1. Solid organ market revenue, by type (2017-2030)
  • 10.5. Market Revenue, by Application (2017-2030)
  • 10.6. Market Revenue, by End User (2017-2030)
  • 10.7. Market Revenue, by Country (2017-2030)

Chapter 11. MEA Market

  • 11.1. Overview
  • 11.2. Market Revenue, by Technology (2017-2030)
    • 11.2.1. Molecular assay market revenue, by type (2017-2030)
    • 11.2.2. Non-molecular assay market revenue, by type (2017-2030)
  • 11.3. Market Revenue, by Offering (2017-2030)
  • 11.4. Market Revenue, by Transplant Type (2017-2030)
    • 11.4.1. Solid organ market revenue, by type (2017-2030)
  • 11.5. Market Revenue, by Application (2017-2030)
  • 11.6. Market Revenue, by End User (2017-2030)
  • 11.7. Market Revenue, by Country (2017-2030)

Chapter 12. U.S. Market

  • 12.1. Overview
  • 12.2. Market Revenue, by Technology (2017-2030)
    • 12.2.1. Molecular assay market revenue, by type (2017-2030)
    • 12.2.2. Non-molecular assay market revenue, by type (2017-2030)
  • 12.3. Market Revenue, by Offering (2017-2030)
  • 12.4. Market Revenue, by Transplant Type (2017-2030)
    • 12.4.1. Solid organ market revenue, by type (2017-2030)
  • 12.5. Market Revenue, by Application (2017-2030)
  • 12.6. Market Revenue, by End User (2017-2030)

Chapter 13. Canada Market

  • 13.1. Overview
  • 13.2. Market Revenue, by Technology (2017-2030)
    • 13.2.1. Molecular assay market revenue, by type (2017-2030)
    • 13.2.2. Non-molecular assay market revenue, by type (2017-2030)
  • 13.3. Market Revenue, by Offering (2017-2030)
  • 13.4. Market Revenue, by Transplant Type (2017-2030)
    • 13.4.1. Solid organ market revenue, by type (2017-2030)
  • 13.5. Market Revenue, by Application (2017-2030)
  • 13.6. Market Revenue, by End User (2017-2030)

Chapter 14. Germany Market

  • 14.1. Overview
  • 14.2. Market Revenue, by Technology (2017-2030)
    • 14.2.1. Molecular assay market revenue, by type (2017-2030)
    • 14.2.2. Non-molecular assay market revenue, by type (2017-2030)
  • 14.3. Market Revenue, by Offering (2017-2030)
  • 14.4. Market Revenue, by Transplant Type (2017-2030)
    • 14.4.1. Solid organ market revenue, by type (2017-2030)
  • 14.5. Market Revenue, by Application (2017-2030)
  • 14.6. Market Revenue, by End User (2017-2030)

Chapter 15. France Market

  • 15.1. Overview
  • 15.2. Market Revenue, by Technology (2017-2030)
    • 15.2.1. Molecular assay market revenue, by type (2017-2030)
    • 15.2.2. Non-molecular assay market revenue, by type (2017-2030)
  • 15.3. Market Revenue, by Offering (2017-2030)
  • 15.4. Market Revenue, by Transplant Type (2017-2030)
    • 15.4.1. Solid organ market revenue, by type (2017-2030)
  • 15.5. Market Revenue, by Application (2017-2030)
  • 15.6. Market Revenue, by End User (2017-2030)

Chapter 16. U.K. Market

  • 16.1. Overview
  • 16.2. Market Revenue, by Technology (2017-2030)
    • 16.2.1. Molecular assay market revenue, by type (2017-2030)
    • 16.2.2. Non-molecular assay market revenue, by type (2017-2030)
  • 16.3. Market Revenue, by Offering (2017-2030)
  • 16.4. Market Revenue, by Transplant Type (2017-2030)
    • 16.4.1. Solid organ market revenue, by type (2017-2030)
  • 16.5. Market Revenue, by Application (2017-2030)
  • 16.6. Market Revenue, by End User (2017-2030)

Chapter 17. Italy Market

  • 17.1. Overview
  • 17.2. Market Revenue, by Technology (2017-2030)
    • 17.2.1. Molecular assay market revenue, by type (2017-2030)
    • 17.2.2. Non-molecular assay market revenue, by type (2017-2030)
  • 17.3. Market Revenue, by Offering (2017-2030)
  • 17.4. Market Revenue, by Transplant Type (2017-2030)
    • 17.4.1. Solid organ market revenue, by type (2017-2030)
  • 17.5. Market Revenue, by Application (2017-2030)
  • 17.6. Market Revenue, by End User (2017-2030)

Chapter 18. Spain Market

  • 18.1. Overview
  • 18.2. Market Revenue, by Technology (2017-2030)
    • 18.2.1. Molecular assay market revenue, by type (2017-2030)
    • 18.2.2. Non-molecular assay market revenue, by type (2017-2030)
  • 18.3. Market Revenue, by Offering (2017-2030)
  • 18.4. Market Revenue, by Transplant Type (2017-2030)
    • 18.4.1. Solid organ market revenue, by type (2017-2030)
  • 18.5. Market Revenue, by Application (2017-2030)
  • 18.6. Market Revenue, by End User (2017-2030)

Chapter 19. Japan Market

  • 19.1. Overview
  • 19.2. Market Revenue, by Technology (2017-2030)
    • 19.2.1. Molecular assay market revenue, by type (2017-2030)
    • 19.2.2. Non-molecular assay market revenue, by type (2017-2030)
  • 19.3. Market Revenue, by Offering (2017-2030)
  • 19.4. Market Revenue, by Transplant Type (2017-2030)
    • 19.4.1. Solid organ market revenue, by type (2017-2030)
  • 19.5. Market Revenue, by Application (2017-2030)
  • 19.6. Market Revenue, by End User (2017-2030)

Chapter 20. China Market

  • 20.1. Overview
  • 20.2. Market Revenue, by Technology (2017-2030)
    • 20.2.1. Molecular assay market revenue, by type (2017-2030)
    • 20.2.2. Non-molecular assay market revenue, by type (2017-2030)
  • 20.3. Market Revenue, by Offering (2017-2030)
  • 20.4. Market Revenue, by Transplant Type (2017-2030)
    • 20.4.1. Solid organ market revenue, by type (2017-2030)
  • 20.5. Market Revenue, by Application (2017-2030)
  • 20.6. Market Revenue, by End User (2017-2030)

Chapter 21. India Market

  • 21.1. Overview
  • 21.2. Market Revenue, by Technology (2017-2030)
    • 21.2.1. Molecular assay market revenue, by type (2017-2030)
    • 21.2.2. Non-molecular assay market revenue, by type (2017-2030)
  • 21.3. Market Revenue, by Offering (2017-2030)
  • 21.4. Market Revenue, by Transplant Type (2017-2030)
    • 21.4.1. Solid organ market revenue, by type (2017-2030)
  • 21.5. Market Revenue, by Application (2017-2030)
  • 21.6. Market Revenue, by End User (2017-2030)

Chapter 22. Australia Market

  • 22.1. Overview
  • 22.2. Market Revenue, by Technology (2017-2030)
    • 22.2.1. Molecular assay market revenue, by type (2017-2030)
    • 22.2.2. Non-molecular assay market revenue, by type (2017-2030)
  • 22.3. Market Revenue, by Offering (2017-2030)
  • 22.4. Market Revenue, by Transplant Type (2017-2030)
    • 22.4.1. Solid organ market revenue, by type (2017-2030)
  • 22.5. Market Revenue, by Application (2017-2030)
  • 22.6. Market Revenue, by End User (2017-2030)

Chapter 23. South Korea Market

  • 23.1. Overview
  • 23.2. Market Revenue, by Technology (2017-2030)
    • 23.2.1. Molecular assay market revenue, by type (2017-2030)
    • 23.2.2. Non-molecular assay market revenue, by type (2017-2030)
  • 23.3. Market Revenue, by Offering (2017-2030)
  • 23.4. Market Revenue, by Transplant Type (2017-2030)
    • 23.4.1. Solid organ market revenue, by type (2017-2030)
  • 23.5. Market Revenue, by Application (2017-2030)
  • 23.6. Market Revenue, by End User (2017-2030)

Chapter 24. Brazil Market

  • 24.1. Overview
  • 24.2. Market Revenue, by Technology (2017-2030)
    • 24.2.1. Molecular assay market revenue, by type (2017-2030)
    • 24.2.2. Non-molecular assay market revenue, by type (2017-2030)
  • 24.3. Market Revenue, by Offering (2017-2030)
  • 24.4. Market Revenue, by Transplant Type (2017-2030)
    • 24.4.1. Solid organ market revenue, by type (2017-2030)
  • 24.5. Market Revenue, by Application (2017-2030)
  • 24.6. Market Revenue, by End User (2017-2030)

Chapter 25. Mexico Market

  • 25.1. Overview
  • 25.2. Market Revenue, by Technology (2017-2030)
    • 25.2.1. Molecular assay market revenue, by type (2017-2030)
    • 25.2.2. Non-molecular assay market revenue, by type (2017-2030)
  • 25.3. Market Revenue, by Offering (2017-2030)
  • 25.4. Market Revenue, by Transplant Type (2017-2030)
    • 25.4.1. Solid organ market revenue, by type (2017-2030)
  • 25.5. Market Revenue, by Application (2017-2030)
  • 25.6. Market Revenue, by End User (2017-2030)

Chapter 26. Saudi Arabia Market

  • 26.1. Overview
  • 26.2. Market Revenue, by Technology (2017-2030)
    • 26.2.1. Molecular assay market revenue, by type (2017-2030)
    • 26.2.2. Non-molecular assay market revenue, by type (2017-2030)
  • 26.3. Market Revenue, by Offering (2017-2030)
  • 26.4. Market Revenue, by Transplant Type (2017-2030)
    • 26.4.1. Solid organ market revenue, by type (2017-2030)
  • 26.5. Market Revenue, by Application (2017-2030)
  • 26.6. Market Revenue, by End User (2017-2030)

Chapter 27. South Africa Market

  • 27.1. Overview
  • 27.2. Market Revenue, by Technology (2017-2030)
    • 27.2.1. Molecular assay market revenue, by type (2017-2030)
    • 27.2.2. Non-molecular assay market revenue, by type (2017-2030)
  • 27.3. Market Revenue, by Offering (2017-2030)
  • 27.4. Market Revenue, by Transplant Type (2017-2030)
    • 27.4.1. Solid organ market revenue, by type (2017-2030)
  • 27.5. Market Revenue, by Application (2017-2030)
  • 27.6. Market Revenue, by End User (2017-2030)

Chapter 28. U.A.E. Market

  • 28.1. Overview
  • 28.2. Market Revenue, by Technology (2017-2030)
    • 28.2.1. Molecular assay market revenue, by type (2017-2030)
    • 28.2.2. Non-molecular assay market revenue, by type (2017-2030)
  • 28.3. Market Revenue, by Offering (2017-2030)
  • 28.4. Market Revenue, by Transplant Type (2017-2030)
    • 28.4.1. Solid organ market revenue, by type (2017-2030)
  • 28.5. Market Revenue, by Application (2017-2030)
  • 28.6. Market Revenue, by End User (2017-2030)

Chapter 29. Competitive Landscape

  • 29.1. List of Market Players and their Offerings
  • 29.2. Competitive Benchmarking of Key Players
  • 29.3. Product Benchmarking of Key Players
  • 29.4. Recent Strategic Developments

Chapter 30. Company Profiles

  • 30.1. bioMerieux S.A.
    • 30.1.1. Business overview
    • 30.1.2. Product and service offerings
    • 30.1.3. Key financial summary
  • 30.2. Thermo Fisher Scientific Inc.
    • 30.2.1. Business overview
    • 30.2.2. Product and service offerings
    • 30.2.3. Key financial summary
  • 30.3. Bio-Rad Laboratories Inc.
    • 30.3.1. Business overview
    • 30.3.2. Product and service offerings
    • 30.3.3. Key financial summary
  • 30.4. Abbott Laboratories
    • 30.4.1. Business overview
    • 30.4.2. Product and service offerings
    • 30.4.3. Key financial summary
  • 30.5. Hologic Inc.
    • 30.5.1. Business overview
    • 30.5.2. Product and service offerings
    • 30.5.3. Key financial summary
  • 30.6. F. Hoffmann-La Roche Ltd.
    • 30.6.1. Business overview
    • 30.6.2. Product and service offerings
    • 30.6.3. Key financial summary
  • 30.7. Laboratory Corporation of America Holdings
    • 30.7.1. Business overview
    • 30.7.2. Product and service offerings
    • 30.7.3. Key financial summary
  • 30.8. BAG Diagnostics GmbH
    • 30.8.1. Business overview
    • 30.8.2. Product and service offerings
    • 30.8.3. Key financial summary
  • 30.9. Illumina Inc.
    • 30.9.1. Business overview
    • 30.9.2. Product and service offerings
    • 30.9.3. Key financial summary

Chapter 31. Appendix

  • 31.1. Abbreviations
  • 31.2. Sources and References
  • 31.3. Related Reports